Ring-substituted diphenylazetidinones, process for their...

Details Ring-substituted diphenylazetidinones, process for their... Ring-substituted diphenylazetidinones, process for their...

2006-10-10

2008-08-05

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C540S200000, C514S016700, C514S017400, C514S018700, C514S019300, C514S210020, C930S280000

Reexamination Certificate

active

07407938

ABSTRACT:
One embodiment of the invention relates to compounds of the formula I,in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.

REFERENCES:
patent: 5656624 (1997-08-01), Vaccaro et al.
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 5889002 (1999-03-01), Nielsen et al.
patent: 6225310 (2001-05-01), Nielsen et al.
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 6498156 (2002-12-01), Glombik et al.
patent: 6632456 (2003-10-01), Backstrom et al.
patent: 6703386 (2004-03-01), Glombik et al.
patent: 2002/0039774 (2002-04-01), Kramer et al.
patent: 2002/0128252 (2002-09-01), Glombik et al.
patent: 2002/0128253 (2002-09-01), Glombik et al.
patent: 2002/0137689 (2002-09-01), Glombik et al.
patent: 2004/0067913 (2004-04-01), Jaehne et al.
patent: 2004/0077623 (2004-04-01), Jaehne et al.
patent: 2004/0082561 (2004-04-01), Jaehne et al.
patent: 2007/0135357 (2007-06-01), Sings et al.
patent: 2007/0142304 (2007-06-01), Alenfalk et al.
patent: 100 64 398 (2002-06-01), None
patent: 101 52 981 (2003-05-01), None
patent: WO 96/19450 (1996-06-01), None
patent: WO 97/16455 (1997-05-01), None
patent: WO 97/26265 (1997-07-01), None
patent: WO 97/41097 (1997-11-01), None
patent: WO 97/45406 (1997-12-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 99/03861 (1999-01-01), None
patent: WO 00/63703 (2000-10-01), None
patent: WO 02/18432 (2002-03-01), None
patent: WO 02/50027 (2002-06-01), None
patent: WO 02/50060 (2002-06-01), None
patent: WO 02/50068 (2002-06-01), None
patent: WO 2004/005247 (2004-01-01), None
Murthy et al., Biochem. J. (2004) 377 (545-552).
Robl et al., J. Med. Chem. 44(6):851-856 (2001) (Abstract only).
Badiu, Endocr Pract. Jan.-Feb. 1999;5(1):10-6 (abstract only).
Moran et al., J Biol Chem, vol. 273, Issue 20, 12259-12266, May 15, 1998.
Shirai, Infect Immun. Nov. 1990;58(11):3568-73.
ChemID Plus Advanced Full record for NMI 8739 (2004).
Kaska, J., M.S. Thesis, Worcester Polytechnic Institute, (2003), including abstract.
esp@cenet abstract of DE 101 52 981, May 8, 2003.
esp@cenet abstract of DE 100 64 398, Jun. 27, 2002.
International Search Report, PCT/EP 03/05816, dated Aug. 28, 2003.
R.M. Castaner et al., “Hypolipidemic Cholesterol Absorption Inhibitor”, Drugs of the Future 2000, 25(7), pp. 679-685, (2000).
A.R. Hilgers, et al., “Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestinal Mucosa”, Pharmaceutical Research, vol. 7, No. 9, pp. 902-910, (1990).
L. Schröder, “The Peptides”, vol. 1, New York 1965, pp. XXII-XXIII, (2000).
Houben-Weyl, Wünsch, “10. Einteilung und Nomenklatur der Peptide und ihrer Derivate,” in Methoden de Organischen Chemie, Stuttgart, Germany, Band XV, Seiten 1 und 2, pp. 1-12, (1974).
Vaccaro, Wayne D., et al., “Sugar-Substituted 2-Azetidinones As Cholesterol Absorption Inhibitors,” Bioorganic & Medicinal Chemistry Letters 8(1998):35-40.
Vaccaro, Wayne D., et al., “Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar,” Bioorganic & Medicinal Chemistry Letters 8(1998):313-318.
van Heek, Margaret et al., “Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and Its glucuronlde, SCH60663,” British Journal of Pharmacology 129:1748-1754 (2000).
Zaks, Aleksey, et al., “Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235,” Applied Biochemistry and Biotechnology, 73:205-213 (1998).

Affiliated with

Also associated with

Rating

Ring-substituted diphenylazetidinones, process for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ring-substituted diphenylazetidinones, process for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ring-substituted diphenylazetidinones, process for their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4011414